WO1998020123A3 - Stable cell lines expressing the cftr protein or a mutant of this protein, tool for selecting molecules having an effect on the intracellular transport of these proteins - Google Patents

Stable cell lines expressing the cftr protein or a mutant of this protein, tool for selecting molecules having an effect on the intracellular transport of these proteins Download PDF

Info

Publication number
WO1998020123A3
WO1998020123A3 PCT/EP1997/006095 EP9706095W WO9820123A3 WO 1998020123 A3 WO1998020123 A3 WO 1998020123A3 EP 9706095 W EP9706095 W EP 9706095W WO 9820123 A3 WO9820123 A3 WO 9820123A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
mutant
proteins
tool
cell lines
Prior art date
Application number
PCT/EP1997/006095
Other languages
French (fr)
Other versions
WO1998020123A2 (en
Inventor
De Beauregard Marie-Alye Costa
Daniel Louvard
Sylvie Robine
Alexandre Edelman
Dominique Chesnoy-Marchais
Ming Chen
Manuel Buchwald
Original Assignee
Inst Curie
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9613416A external-priority patent/FR2755446B1/en
Application filed by Inst Curie, Centre Nat Rech Scient filed Critical Inst Curie
Publication of WO1998020123A2 publication Critical patent/WO1998020123A2/en
Publication of WO1998020123A3 publication Critical patent/WO1998020123A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/382—Cystic fibrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to a recombinant nucleic acid, characterized in that it comprises: a nucleotide sequence encoding (coding sequence) the normal CFTR protein, an epitope sequence located at the 3' end of the abovementioned coding sequence, a strong promoter sequence capable of controlling the expression of the abovementioned coding sequence and epitope sequence, when they are integrated into a determined cell.
PCT/EP1997/006095 1996-11-04 1997-11-04 Stable cell lines expressing the cftr protein or a mutant of this protein, tool for selecting molecules having an effect on the intracellular transport of these proteins WO1998020123A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR96/13416 1996-11-04
FR9613416A FR2755446B1 (en) 1996-11-04 1996-11-04 STABLE CELL LINES EXPRESSING THE CFTR PROTEIN OR A MUTANT OF THIS PROTEIN, TOOL FOR THE SELECTION OF MOLECULES HAVING AN EFFECT ON THE INTRACELLULAR TRANSPORT OF THESE PROTEINS
US08/874,040 1997-06-12
US08/874,040 US5888722A (en) 1996-11-04 1997-06-12 Stable cell lines expressing the CFTR protein or a mutant of this protein, tool for selecting molecules having an effect on the intracellular transport of these proteins

Publications (2)

Publication Number Publication Date
WO1998020123A2 WO1998020123A2 (en) 1998-05-14
WO1998020123A3 true WO1998020123A3 (en) 1998-07-02

Family

ID=26233083

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/006095 WO1998020123A2 (en) 1996-11-04 1997-11-04 Stable cell lines expressing the cftr protein or a mutant of this protein, tool for selecting molecules having an effect on the intracellular transport of these proteins

Country Status (1)

Country Link
WO (1) WO1998020123A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
FR2861991B1 (en) * 2003-11-07 2008-01-18 Centre Nat Rech Scient USE OF GLUCOSIDASE INHIBITORS FOR MUCOVISCIDOSE THERAPY

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004671A1 (en) * 1992-08-26 1994-03-03 Genzyme Corporation Methods and therapeutic compositions for treating cystic fibrosis
WO1995005810A1 (en) * 1993-08-26 1995-03-02 National Research Council Of Canada Compositions and methods for the detection and treatment of protein trafficking disorders and increasing secretory protein production

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004671A1 (en) * 1992-08-26 1994-03-03 Genzyme Corporation Methods and therapeutic compositions for treating cystic fibrosis
WO1995005810A1 (en) * 1993-08-26 1995-03-02 National Research Council Of Canada Compositions and methods for the detection and treatment of protein trafficking disorders and increasing secretory protein production

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BERGERON J J M ET AL: "CALNEXIN: A MEMBRANE-BOUND CHAPERONE OF THE ENDOPLASMIC RETICULUM", TIBS TRENDS IN BIOCHEMICAL SCIENCES, vol. 19, no. 3, 1 March 1994 (1994-03-01), pages 124 - 128, XP000429323 *
HAMMOND, CRAIG ET AL: "Folding of VSV G protein: sequential interaction with BiP and calnexin", SCIENCE (WASHINGTON, D. C.) ( 1994 ), 266(5184), 456-8 CODEN: SCIEAS;ISSN: 0036-8075, 1994, XP002035741 *
HAMMOND, CRAIG ET AL: "Role of N-linked oligosaccharide recognition, glucose trimming, and calnexin in glycoprotein folding and quality control", PROC. NATL. ACAD. SCI. U. S. A. ( 1994 ), 91(3), 913-17 CODEN: PNASA6;ISSN: 0027-8424, 1994, XP002035740 *
M.R. JACKSON ET AL.: "Regulation of MHC class I transport by the molecular chaperone, calnexin (p88, IP90)", SCIENCE, vol. 263, 21 January 1994 (1994-01-21), AAAS,WASHINGTON,DC,US, pages 384 - 387, XP002035742 *
S. PIND ET AL.: "Participation of the endoplasmic reticulum chaperone calnexin (p88, IP90) in the biogenesis of the cystic fibrosis transmembrane conductance regulator", J. BIOL. CHEM., vol. 269, no. 17, 29 April 1994 (1994-04-29), AM. SOC. BIOCHEM. MOL.BIOL.,INC.,BALTIMORE,US, pages 12784 - 12788, XP002035738 *
S. RAJAGOPALAN ET AL.: "Retention of unassembled componnets of integral membrane proteins by calnexin", SCIENCE, vol. 263, 21 January 1994 (1994-01-21), AAAS,WASHINGTON,DC,US, pages 387 - 390, XP002035743 *
S. ROBINE ET AL.: "Regulatory sequences on the human villin gene trigger the expression of a reporter gene in a differentiating HT29 intestinal cell line", J. BIOL. CHEM., vol. 268, no. 15, 25 May 1993 (1993-05-25), AM. SOC. BIOCHEM. MOL.BIOL.,INC.,BALTIMORE,US, pages 11426 - 11434, XP002035739 *
T.E. KREIS: "Microinjected antibodies against the cytoplasmic domain of vesicular stomatitis virus glycoprotein block its transport to the cell surface", EMBO J., vol. 5, no. 5, May 1986 (1986-05-01), OXFORD UNIVERSITY PRESS,GB;, pages 931 - 941, XP002035744 *
Y. YANG ET AL.: "The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment", PROC. NATL.ACAD SCI., vol. 90, no. 20, 15 October 1993 (1993-10-15), NATL. ACAD SCI.,WASHINGTON,DC,US;, pages 9480 - 9484, XP002035737 *

Also Published As

Publication number Publication date
WO1998020123A2 (en) 1998-05-14

Similar Documents

Publication Publication Date Title
CA2265976A1 (en) High level expression of proteins
HK1040401A1 (en) Isolated nucleic acid molecules which encode t cell inducible factors (tifs), the proteins encoded, and uses thereof
AU4978496A (en) Encapsidated recombinant poliovirus nucleic acid
WO2000005367A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
WO1994003616A3 (en) Cloning and/or sequencing vector
AU3509995A (en) Overexpression of mammalian and viral proteins
EP1132479A4 (en) Protein expression vector and utilization thereof
WO2001064882A3 (en) 1983, 52881, 2398, 45449, 50289, and 52872, g protein-coupled receptors and uses therefor
WO2003060143A3 (en) Efficient protein expression system
WO2001049713A3 (en) Stabilizing peptides, polypeptides and antibodies which include them
WO1996007739A3 (en) Interleukin-1 type 3 receptors
WO2000029448A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
AU5906699A (en) (neisseria spp.) polypeptide, nucleic acid sequence and uses thereof
AU7001994A (en) Mutant polypeptide of protein kinase c, nucleic acid sequences coding for said polypeptide and use thereof
CA2204151A1 (en) Cdna encoding a bmp type ii receptor
AU4375493A (en) Isolated protein receptors, antibodies which bind thereto, nucleic acid sequence coding therefor, and uses thereof
AU3711597A (en) A novel galanin receptor
WO1998020123A3 (en) Stable cell lines expressing the cftr protein or a mutant of this protein, tool for selecting molecules having an effect on the intracellular transport of these proteins
EP1251176A3 (en) Expression systems utilizing autolyzing fusion proteins and a reducing polypeptide
WO2000020450A3 (en) Calcium channel alpha-2/delta gene
WO1996005300A3 (en) Or-1 on orphan receptor belonging to the nuclear receptor family
CA2194032A1 (en) Fused dna sequence, fused protein expressed from said fused dna sequence and method for expressing said fused protein
EP0816498A3 (en) Excitatory amino acid receptor protein and related nucleic acid compounds
AU7753700A (en) Dna encoding prost 07 polypeptide
WO2001094390A3 (en) 52906, 33408, and 12189, potassium channel family members and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA